Key Targets for Immunotherapeutic Development

By Terryberry, B.S. and G. Thor Ph D.

Published: November, 2003

1,200+ Pages - 110+ Exhibits - 70 Companies Profiled 

The cytokines, chemokines, and growth factors market has $90 billion revenue potential.

Cytokine-based research is revolutionizing the treatment of inflammatory, infectious, and neoplastic diseases. Many of the original cytokine treatments (i.e. interferon-1beta, and TNF-alpha) have given way to more refined approaches as the knowledge and discovery process concerning complex cytokine and chemokine networks becomes further clarified. The increased market penetration of approved drugs targeting cytokines and their receptors has spurred several pharmaceutical companies to devote a portion of their pipelines to the development of these immunotherapeutics.

 

D&MD's Cytokines, Chemokines, and Growth Factors Market Analysis Report provides a thorough review of this promising drug target class. This Report will help you: 

Pinpoint the full market potential of cytokine- and chemokine-based drugs with an examination of the projected market impact through 2009.

Identify commercial opportunities for immunotherapeutic drug technologies via a thorough assessment of current and emerging drug development platforms, including particular immunodiagnostics utilized to discover novel cytokine drugs.

Discover what's new in the industry with a comprehensive update and discussion of novel cytokine, chemokine and growth factor classification and nomenclature schemes.

Obtain a complete and extensive appraisal of the development status for all cytokine-based drugs and clinical trials of all phases, including pre-clinical studies, via a meta-analysis of each disease application and investigated cytokine.

Get an up-to-date review of pathogenic cytokine findings through an evaluation of the latest developments critical to novel cytokine-based products and clinical trials, including a prodigious list of references and key Web site links.

Identify trends in each of the immunotherapeutic sub-sectors with an in-depth review of monoclonals, receptor antagonists, small molecule growth factors, signal cascades, ex vivo cell transfer, and gene therapy

Learn about the current patent and licensing landscape of immunotherapeutics from a critical evaluation of patent issues, licensing agreements, and partnerships of immunotherapeutic companies, including associated marketing profiles of major immunotherapeutic/biologicals companies.

Look inside 70 companies utilizing cytokines and chemokines for drug development, including their product pipelines, financial standing, partnerships & alliances, and more. 

Publisher: Drug and Market Development 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/DMD_2003.html#a32